DexCom stock: buy or sell?
August 23rd, 2019
DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Should I buy DexCom stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
These 3 buy setups work for DexCom stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||Yes|
Is DexCom stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 15 ratings published for DXCM stock in the last month. The general sentiment of these ratings is bullish for DXCM stock, with 11 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-1||Robert W. Baird||n/a||Outperform|
|2019-8-1||JPMorgan Chase & Co.||n/a||Overweight|
|2019-8-1||Bank of America||n/a||Buy|
|2019-1-9||Piper Jaffray Companies||Average||Overweight|
DexCom stock analysis
DexCom closed today at $173.55 after marking a new all time high ($176.59) even it couldn't close with gains and depreciated a lame -0.47%.
Even the red candle ($173.55, -0.47%), DexCom marked new all time high at $176.59. Since last August/21 when SMA100d and SMA200d crossed up, DXCM price gained $5.27 per share (3.13%). Since price and SMA200d lines crossed up on June, DXCM climbed $47.57 (37.76%).
DexCom reached new all time highs again this week, setting highs to $176.59. Shares ended at $173.55 and rocketed 6.03% during the week. Late July DXCM plummed a hair-raising -6.63% in just one week. This week was the third green week in a row.
Since SMA20d and SMA40w crossed up last week, DXCM price climbed $18.11 per share (11.65%). Since mid June when DXCM stock price broke up the SMA40w line, it gained $47.57 (37.76%).
DexCom stock price history
DexCom IPO was on April 14th, 2005 at $12.08 per share1. Since then, DXCM stock surged a 1,336.70%, with a yearly average of 95.50%. If you had invested $1,000 in DexCom stock in 2005, it would worth $13,367.00 today.
1: Adjusted price after possible price splits or reverse-splits.
DexCom stock historical price chart
DXCM stock reached all-time highs today with a price of $176.59.
DexCom stock price target is $166.30Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' DXCM stock price predictions in the hope that they will be met as they may be wrong and not met. We found 14 price predictions for DexCom stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-1||UBS Group||Raises Target||$140.00||$160.00||14.3%|
|2019-8-1||Robert W. Baird||Raises Target||$180.00||$186.00||3.3%|
|2019-8-1||Raymond James||Raises Target||$150.00||$172.00||14.7%|
|2019-8-1||JPMorgan Chase & Co.||Raises Target||$170.00||$190.00||11.8%|
|2019-8-1||Bank of America||Raises Target||$162.00||$185.00||14.2%|
|2019-5-2||Raymond James||Lowers Target||$160.00||$150.00||-6.3%|
|2019-4-30||UBS Group||Lowers Target||$150.00||$140.00||-6.7%|
|2019-2-22||Canaccord Genuity||Raises Target||$140.00||$160.00||14.3%|
|2019-1-9||Piper Jaffray Companies||Raises Target||n/a||$165.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, DexCom presented its financial report, posting an astounding climb for the Earnings per Share (EPS) ratio. Experts expected $0.16 per share, but DexCom posted $0.54.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a super good gain of 43.58% to $1,031.60 M dollars. On the other hand, its income margin (compared to sales) dropped to -12.32%, that is $-127.10 million.
|2013||$160 M||-||$-29.80 M-18.6%||-|
|2014||$259 M||62.00%||$-22.40 M-8.6%||-24.83%|
|2015||$402 M||55.09%||$-57.60 M-14.3%||157.14%|
|2016||$573 M||42.61%||$-65.60 M-11.4%||13.89%|
|2017||$719 M||25.33%||$-50.20 M-7.0%||-23.48%|
|2018||$1,032 M||43.58%||$-127.10 M-12.3%||153.19%|
Quarterly financial resultsDexCom reported $338.00 M in sales for 2018-Q4, a 26.73% improvement compared to previous quarter. Reported quarter earnings marked $-179.70 million with a profit margin of -53.17%. Profit margin plummed a -70.64% compared to previous quarter when profit margin was 17.47%. When comparing sales to same quarter last year, DexCom sales marked an exceptional growth and rocketed a 52.94%. Looking back to recent quarterly results, DexCom posted 3 negative quarters in a row.
|2017-Q2||$171 M||-||$2.90 M1.7%||-|
|2017-Q3||$185 M||8.21%||$-2.00 M-1.1%||-168.97%|
|2017-Q4||$221 M||19.72%||$-9.40 M-4.3%||370.00%|
|2018-Q1||$184 M||-16.56%||$-24.20 M-13.1%||157.45%|
|2018-Q2||$243 M||31.51%||$30.20 M12.5%||-224.79%|
|2018-Q3||$267 M||9.98%||$46.60 M17.5%||54.30%|
|2018-Q4||$338 M||26.73%||$-179.70 M-53.2%||-485.62%|
|2019-Q1||$281 M||-17.01%||$-26.90 M-9.6%||-85.03%|
DexCom ownershipWhen you are planning to invest in a company, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For DexCom, 1.14% of all outstanding shares are owned by its staff.
Bearish positions for DXCM stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to DexCom:
|Market cap||$15.8 B||$148.5 B||$67.0 B||$44.1 B||$349.2 B|
|Total shares||91.1 M||1,760.0 M||269.7 M||208.1 M||2,660.0 M|
|Float shares||90.0 M||1,750.0 M||269.1 M||206.6 M||2,630.0 M|
|- Institutional holdings (%)||100.2%||76.5%||87.5%||0.0%||69.2%|
|- Insider holdings (%)||1.1%||0.7%||0.3%||3.9%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, August 23rd, 2019|
|Day range||$172.45 - $176.59|
|Average true range||$5.59|
|50d mov avg||$152.73|
|100d mov avg||$136.86|
|200d mov avg||$135.78|
DexCom performanceTo better understand DexCom performance you must compare its gains with other related stocks in same sector or industry. We compared DexCom against , Becton, Dickinson and, Edwards Lifesciences, , Medtronic, Quidel, Tandem Diabetes Care and West Pharmaceutical Services in the following table:
|TNDMTandem Diabetes C...||2.22%||38.27%||74.12%|
DexCom competitorsWe picked a few stocks to conform a list of DexCom competitors to review if you are interested in investing in DXCM:
- Becton, Dickinson and (BDX)
- Edwards Lifesciences (EW)
- Medtronic (MDT)
- Quidel (QDEL)
- Tandem Diabetes Care (TNDM)
- West Pharmaceutical Services (WST)
Latest DexCom stock news
- InvestorPlaceDexCom Stock Skyrockets on Q2 Earnings BeatAugust 2, 2018